Filing Flows

Filing Flows › Companies › Xenetic Biosciences › Cash flow

Xenetic Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$875K in Q2 2026 · −$2.3M over twelve months

Operating cash flow−$875K
Free cash flow−$875K

Analysis

In Q2 2026, Xenetic Biosciences generated −$875K of operating cash flow. That is $492K less than in Q2 2025 (−$384K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$2.3M; the largest uses were operating cash flow ($2.3M); the cash balance rose by $1.7M.

Operating cash flow was −$875K against net income of −$930K. The largest differences: prepaid and other assets +$66K, payables −$63K, stock-based pay +$52K.

Free cash flow

Xenetic Biosciences: free cash flow by quarterXenetic Biosciences: free cash flow by quarter−$459KQ3 2024−$674KQ4 2024−$1.0MQ1 2025−$384KQ2 2025−$658KQ3 2025−$243KQ4 2025−$536KQ1 2026−$875KQ2 2026
Operating cash flow less capital spending.
Xenetic Biosciences: operating cash flow against capital spendingXenetic Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$459K$0Q3 2024−$674K$0Q4 2024−$1.0M$0Q1 2025−$384K$0Q2 2025−$658K$0Q3 2025−$243K$0Q4 2025−$536K$0Q1 2026−$875K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$875K, Capital spending $0.

Capital allocation, year by year

Xenetic Biosciences: where the cash came from (up) and went (down), by fiscal yearXenetic Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2021: Operating cash flow −$4.7MFY2021: Net borrowing $100KFY2021: Shares issued $11.5M$11.6MFY2021FY2022: Operating cash flow −$4.6MFY2022FY2023: Operating cash flow −$4.1MFY2023FY2024: Operating cash flow −$2.8MFY2024FY2025: Operating cash flow −$2.3MFY2025: Shares issued $4.0M$4.0MFY2025
Over these 5 years operating cash flow totalled −$18.6M; the largest uses were operating cash flow ($18.6M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$6.5M
Debtnone
Net cash$6.5M
Cash runway2.8 years

Xenetic Biosciences is burning cash: its operations consume cash, a free cash flow of −$2.3M a year at the current rate against $6.5M of cash and investments: a runway of about 2.8 years before any new financing.

Where the cash came from and went

Xenetic Biosciences: sources (+) and uses (−) of cash, Q2 2026Xenetic Biosciences: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$875KCash drawn (+) / kept (−)$875K
Xenetic Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Xenetic Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Not reconciled$4.0MOperating cash flow−$2.3MCash drawn (+) / kept (−)−$1.7M

From profit to cash

Xenetic Biosciences: net income to operating cash flow, Q2 2026Xenetic Biosciences: net income to operating cash flow, Q2 2026Net income−$930KStock-based pay$52KPayables−$63KPrepaid and other assets$66KOperating cash flow−$875K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q2 2026−$875K$875K−$875K
Q1 2026−$536K$536K−$536K
Q4 2025−$243K−$3.8M−$243K
Q3 2025−$658K$658K−$658K
Q2 2025−$384K$384K−$384K
Q1 2025−$1.0M$1.0M−$1.0M
Q4 2024−$674K$674K−$674K
Q3 2024−$459K$459K−$459K

Xenetic Biosciences: income statement and cash flow

Xenetic Biosciences, Q2 2026: revenue $661K (+12% year over year), operating margin -147.1%. The chart follows the revenue to costs, profit and cash.

Xenetic Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.